Payment overview · 2025
General Payments
$20,705.21
283 reported records · 27 companies
Healthcare provider profile · identity verified
Farhad Kadkhodaei Elyaderani, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Clinical Neurophysiology · BRONX, NY · NPI 1396972725
Verified facts
What the public records show
CMS Open Payments records show Farhad Kadkhodaei Elyaderani, MD received $20,705.21 in general payments during 2025 across 283 reported records.
PFIZER INC. accounted for 75.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Gocovri, Nuplazid, Nurtec Odt, Rexulti, Zavzpret, Ztlido.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 453 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 481 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Vraylar by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nuplazid by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rytary by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rexulti by this doctor in 2024.
MDD US Operations, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gocovri as an associated drug or biological on 3202 records involving 1029 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Gocovri by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rexulti by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZAVZPRET as an associated drug or biological on 140787 records involving 33518 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Zavzpret by this doctor in 2024.
SCILEX PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZTLido as an associated drug or biological on 6923 records involving 3060 distinct recipient NPIs. Public Medicare Part D data also shows 267 claims for Ztlido by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xcopri by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $15,564.83 | 75.2% | 59 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $1,388.21 | 6.7% | 13 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $485.48 | 2.3% | 23 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $364.92 | 1.8% | 19 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $341.56 | 1.6% | 27 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $340.91 | 1.6% | 25 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$320.59 | 1.6% | 22 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $303.94 | 1.5% | 19 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $234.98 | 1.1% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $227.81 | 1.1% | 19 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $224.87 | 1.1% | 8 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $215.70 | 1.0% | 9 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $142.07 | 0.7% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $122.85 | 0.6% | 5 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $64.58 | 0.3% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $60.95 | 0.3% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $51.66 | 0.2% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $36.64 | 0.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.29 | 0.1% | 1 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $29.71 | 0.1% | 1 | 2025 |
| Ultragenyx Pharmaceutical Inc. | Unresolved — no canonical attribution shown | $26.43 | 0.1% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $24.19 | 0.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $23.53 | 0.1% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $21.34 | 0.1% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $19.59 | 0.1% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $18.98 | 0.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.60 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $13,685.90 | 7 |
| Food and Beverage | $5,494.31 | 275 |
| Consulting Fee | $1,525.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $10,630.30 | 47 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $5,751.25 | 53 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $1,388.21 | 13 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $364.92 | 19 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $340.91 | 25 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $303.94 | 19 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $286.48 | 25 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $224.87 | 8 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $211.10 | 12 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $188.48 | 13 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $182.68 | 8 | 2025 |
Source payment records
|
|||||
| ELYXYB - CELECOXIB Normalized: elyxyb celecoxib |
Drug | SCILEX PHARMACEUTICALS INC. | $156.29 | 13 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $142.07 | 5 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $122.85 | 5 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $106.21 | 8 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $88.10 | 3 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $88.10 | 3 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $70.87 | 3 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $64.58 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $60.95 | 3 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $51.66 | 2 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $44.76 | 2 | 2025 |
Source payment records
|
|||||
| EMGALITY Normalized: emgality |
Drug | Lilly USA, LLC | $39.33 | 6 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $36.64 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $31.29 | 1 | 2025 |
Source payment records
|
|||||
| Dysport Normalized: dysport |
Drug | Ipsen Biopharmaceuticals, Inc | $29.71 | 1 | 2025 |
Source payment records
|
|||||
| Dojolvi Normalized: dojolvi |
Drug | Ultragenyx Pharmaceutical Inc. | $26.43 | 1 | 2025 |
Source payment records
|
|||||
| REJOYN Normalized: rejoyn |
Device | Otsuka Pharmaceutical Development & Commercialization, Inc. | $24.19 | 1 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $23.88 | 1 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $21.34 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $19.59 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $17.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 63 | exact normalized | Medicare Part D |
| Gocovri gocovri |
2025 | Gocovri | 2024 | 128 | exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 170 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZAVZPRET zavzpret |
2025 | Zavzpret | 2024 | 61 | exact normalized | Medicare Part D |
| ZTLido ztlido |
2025 | Ztlido | 2024 | 267 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
63 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
453 | 106 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
481 | 131 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
123 | 28 |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| MDD US Operations, LLC Exact reporting entity; no affiliate inference |
2025 | Gocovri open payments reported associated product |
CMS Open Payments — General Payments 3202 supporting records · 1029 recipient NPIs · example record 1241843637 |
Gocovri · 2024 Exact normalized brand match · 1 Part D row |
128 | 17 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
170 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ZAVZPRET open payments reported associated product |
CMS Open Payments — General Payments 140787 supporting records · 33518 recipient NPIs · example record 1228794071 |
Zavzpret · 2024 Exact normalized brand match · 1 Part D row |
61 | 20 |
| SCILEX PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | ZTLido open payments reported associated product |
CMS Open Payments — General Payments 6923 supporting records · 3060 recipient NPIs · example record 1242585247 |
Ztlido · 2024 Exact normalized brand match · 1 Part D row |
267 | 84 |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Carbidopa-Levodopa | Carbidopa/Levodopa | 664 | 119 |
| Ubrelvy | Ubrogepant | 481 | 131 |
| Qulipta | Atogepant | 453 | 106 |
| Memantine Hcl | Memantine Hcl | 452 | 80 |
| Gabapentin | Gabapentin | 362 | 76 |
| Donepezil Hcl | Donepezil Hcl | 327 | 64 |
| Ztlido | Lidocaine | 267 | 84 |
| Meclizine Hcl | Meclizine Hcl | 228 | 53 |
| Levetiracetam | Levetiracetam | 217 | 31 |
| Nurtec Odt | Rimegepant Sulfate | 170 | 40 |
| Quetiapine Fumarate | Quetiapine Fumarate | 153 | 33 |
| Naproxen | Naproxen | 152 | 40 |
| Emgality Pen | Galcanezumab-Gnlm | 130 | 29 |
| Gocovri | Amantadine Hcl | 128 | 17 |
| Aimovig Autoinjector | Erenumab-Aooe | 126 | 20 |
| Vraylar | Cariprazine Hcl | 123 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 120 | 29 |
| Elyxyb | Celecoxib | 105 | 27 |
| Doxepin Hcl | Doxepin Hcl | 98 | 41 |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 79 | 26 |
| Budesonide Er | Budesonide | 69 | 23 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 67 | 28 |
| Oxcarbazepine | Oxcarbazepine | 67 | suppressed |
| Botox | Onabotulinumtoxina | 63 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 61 | 13 |
| Zavzpret | Zavegepant Hcl | 61 | 20 |
| Carbamazepine | Carbamazepine | 57 | suppressed |
| Ajovy Syringe | Fremanezumab-Vfrm | 52 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 52 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 18 |
| Rasagiline Mesylate | Rasagiline Mesylate | 49 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 44 | suppressed |
| Pregabalin | Pregabalin | 42 | 11 |
| Phenobarbital | Phenobarbital | 39 | suppressed |
| Zonisamide | Zonisamide | 37 | suppressed |
| Mirtazapine | Mirtazapine | 36 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 35 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Lidocaine | Lidocaine | 34 | 15 |
| Naproxen Sodium Er | Naproxen Sodium | 34 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 34 | suppressed |
| Topiramate | Topiramate | 34 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 34 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 31 | suppressed |
| Amantadine | Amantadine Hcl | 26 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Fluocinonide | Fluocinonide | 25 | 17 |
| Rytary | Carbidopa/Levodopa | 25 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Piroxicam | Piroxicam | 20 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 18 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 17 | suppressed |
| Dalfampridine Er | Dalfampridine | 16 | suppressed |
| Rexulti | Brexpiprazole | 16 | suppressed |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 14 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 14 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Xcopri | Cenobamate | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 11 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $20,705.21 · 283 records | PFIZER INC. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, AMYVID, AUSTEDO XR, BOTOX, BRIUMVI, CAPLYTA, COBENFY, CREXONT, DAYBUE, Dojolvi, Dysport, ELYXYB - CELECOXIB, EMGALITY, FANAPT, Gamunex-C, Gocovri, HETLIOZ, HYQVIA, KESIMPTA, KISUNLA, Leqembi, NUPLAZID, NURTEC ODT, Ocrevus Zunovo, REJOYN, REXULTI, Symbravo, ULTOMIRIS, UPLIZNA, VYEPTI, WAINUA, ZAVZPRET, ZTLido | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error